

# CACYBP antibody - middle region

Rabbit Polyclonal Antibody

Catalog # AI13288

## Product Information

---

<b>Application</b>	WB
<b>Primary Accession</b>	<a href="#">Q9HB71</a>
<b>Other Accession</b>	<a href="#">NM_014412</a> , <a href="#">NP_055227</a>
<b>Reactivity</b>	Human, Mouse, Rat, Rabbit, Pig, Dog, Guinea Pig, Horse, Bovine
<b>Predicted</b>	Human, Rabbit, Chicken, Dog, Guinea Pig, Horse
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	26210

## Additional Information

---

<b>Gene ID</b>	27101
<b>Alias Symbol</b> <b>Other Names</b>	GIG5, MGC87971, PNAS-107, RP1-102G20.6, S100A6BP, SIP Calcyclin-binding protein, CacyBP, hCacyBP, S100A6-binding protein, Siah-interacting protein, CACYBP, S100A6BP, SIP
<b>Format</b>	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
<b>Reconstitution &amp; Storage</b>	Add 100 ul of distilled water. Final anti-CACYBP antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
<b>Precautions</b>	CACYBP antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information


---

<b>Name</b>	CACYBP
<b>Synonyms</b>	S100A6BP, SIP
<b>Function</b>	May be involved in calcium-dependent ubiquitination and subsequent proteasomal degradation of target proteins. Probably serves as a molecular bridge in ubiquitin E3 complexes. Participates in the ubiquitin-mediated degradation of beta-catenin (CTNNB1).
<b>Cellular Location</b>	Nucleus. Cytoplasm. Note=Cytoplasmic at low calcium concentrations. In neuroblastoma cells, after a retinoic acid (RA) induction and calcium increase, it localizes in both the nucleus and cytoplasm. The nuclear fraction may be

phosphorylated

## Images

---



WB Suggested Anti-CACYBP Antibody Titration: 5.0µg/ml  
Positive Control: HepG2 cell lysate

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.